RHHBF - Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

2024-06-14 13:26:47 ET

Summary

• Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP.
• Potential FDA feedback to initiate a pivotal study using bitopertin for the treatment of patients with EPP and XLP expected in the 2nd half of 2024.
• Results from the phase 1/2 study, using DISC-0974 for the treatment of patients with NDD-CKD, expected in the 2nd half of 2024.
• Initial pharmacokinetic and pharmacodynamic data from the phase 1 healthy volunteer study for iron overload disorders expected in Q2 of 2024.

The last time I spoke about Disc Medicine ( IRON ) was in a Seeking Alpha article known as " Disc Medicine: Rare Disease Biotech With Enormous Potential . " In the article, I laid out that IRON had already reported positive results from its phase 2 BEACON study using its drug bitopertin for the treatment of patients with erythropoietic protoporphyria [EPP] and X-linked protoporphyria [XLP]. However, it had not yet released results from its phase 2 AURORA trial, which is also used this drug to treat both of these patient populations. I'm pleased to report that this company was able to release positive results from this randomized, placebo-controlled study....

For further details see: